The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. NovoCure P/E ratio is -130.32. it has increased by a third in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into NovoCure’s P/E ratio

**Contents**hide

## What is NovoCure P/E Ratio?

NovoCure’s P/E ratio is -130.32, which represents a 66.75% increase over the same period last year. their average P / E ratio is 257.71 for the 1-year period and the 5-year average is 13.14.

## What is NovoCure Net EPS?

NovoCure’s net earnings for the most recent quarter were -0.57$, which represents a 1325.0% decrease from the same period last year.

## Who are NovoCure Competitors?

Based on Jika.io AI model, MicroPort CardioFlow Medtech, Axonics, Glaukos, Hologic, Inspire Medical Systems, Inari Medical, QuidelOrtho are considered to be NovoCure’s competitors because the companies operate within the same industry as NovoCure and they are targeting the same customer base. in addition, competitors typically share a similar market capitalization as NovoCure.

## Who is NovoCure’s Biggest competitor?

NovoCure’s biggest competitor is MicroPort CardioFlow Medtech, based on the Jika.io AI model. it has a similar market capitalization to NovoCure in the industry, it dominates a similar share of the market as NovoCure, and it provides and markets very similar services.

## What industry is NovoCure in?

NovoCure is part of the Medical Instruments & Supplies industry and the Healthcare sector.

## NovoCure vs MicroPort CardioFlow Medtech

Market Cap: NovoCure’s Market Cap of 7723676160 is higher than MicroPort CardioFlow Medtech Market Cap of 7523142656.

Average Volume: NovoCure’s Average Volume of 698150.0 is higher than MicroPort CardioFlow Medtech Average Volume of 6.798M.

Beta: NovoCure’s Beta of 0.88 is higher than MicroPort CardioFlow Medtech Beta of 0.0.

Revenue: NovoCure’s Revenue of 535.031M is higher than MicroPort CardioFlow Medtech Revenue of 200.813M.

Net Income: NovoCure’s Net Income of -58.351M is higher than MicroPort CardioFlow Medtech Net Income of -183.264M.

Gross Profit: NovoCure’s Gross Profit of 420.154M is higher than MicroPort CardioFlow Medtech Gross Profit of 118.701M.

Ebitda: NovoCure’s Ebitda of -38.384M is higher than MicroPort CardioFlow Medtech Ebitda of -118.589M.

ROE: NovoCure’s ROE of -0.14 is lower than MicroPort CardioFlow Medtech ROE of 0.0.

ROA: NovoCure’s ROA of -0.05 is lower than MicroPort CardioFlow Medtech ROA of 0.0.

Return On Capital Employed: NovoCure’s Return On Capital Employed of -0.04 is lower than MicroPort CardioFlow Medtech Return On Capital Employed of 0.0.

Assets (Total): NovoCure’s Assets (Total) of 1.139B is lower than MicroPort CardioFlow Medtech Assets (Total) of 3.362B.

Debt (Total): NovoCure’s Debt (Total) of 575.213M is higher than MicroPort CardioFlow Medtech Debt (Total) of 125.635M.

Shareholders Equity: NovoCure’s Shareholders Equity of 410.494M is higher than MicroPort CardioFlow Medtech Shareholders Equity of 3.096B.

## NovoCure vs Axonics

Market Cap: NovoCure’s Market Cap of 7723676160 is higher than Axonics Market Cap of 2962592000.

Average Volume: NovoCure’s Average Volume of 698150.0 is higher than Axonics Average Volume of 571458.0.

Beta: NovoCure’s Beta of 0.88 is higher than Axonics Beta of 0.51.

Revenue: NovoCure’s Revenue of 535.031M is higher than Axonics Revenue of 180.29M.

Net Income: NovoCure’s Net Income of -58.351M is lower than Axonics Net Income of -80.067M.

Gross Profit: NovoCure’s Gross Profit of 420.154M is higher than Axonics Gross Profit of 115.718M.

Ebitda: NovoCure’s Ebitda of -38.384M is lower than Axonics Ebitda of -62.733M.

P/E Ratio: NovoCure’s P/E Ratio of -130.32 is lower than Axonics P/E Ratio of -35.41.

P/S Ratio: NovoCure’s P/S Ratio of 14.26 is lower than Axonics P/S Ratio of 14.62.

P/B Ratio: NovoCure’s P/B Ratio of 17.6 is lower than Axonics P/B Ratio of 6.13.

P/FCF Ratio: NovoCure’s P/FCF Ratio of 213.07 is higher than Axonics P/FCF Ratio of -85.27.

ROE: NovoCure’s ROE of -0.14 is lower than Axonics ROE of -0.17.

ROA: NovoCure’s ROA of -0.05 is lower than Axonics ROA of -0.15.

Return On Capital Employed: NovoCure’s Return On Capital Employed of -0.04 is lower than Axonics Return On Capital Employed of -0.15.

Gross Profit Margin: NovoCure’s Gross Profit Margin of 0.78 is higher than Axonics Gross Profit Margin of 0.66.

Assets (Total): NovoCure’s Assets (Total) of 1.139B is lower than Axonics Assets (Total) of 547.945M.

Debt (Total): NovoCure’s Debt (Total) of 575.213M is higher than Axonics Debt (Total) of 10.418M.

Shareholders Equity: NovoCure’s Shareholders Equity of 410.494M is lower than Axonics Shareholders Equity of 482.438M.

## NovoCure vs Glaukos

Market Cap: NovoCure’s Market Cap of 7723676160 is higher than Glaukos Market Cap of 2217105920.

Average Volume: NovoCure’s Average Volume of 698150.0 is higher than Glaukos Average Volume of 497846.0.

Beta: NovoCure’s Beta of 0.88 is lower than Glaukos Beta of 1.53.

Revenue: NovoCure’s Revenue of 535.031M is higher than Glaukos Revenue of 294.011M.

Net Income: NovoCure’s Net Income of -58.351M is higher than Glaukos Net Income of -49.593M.

Gross Profit: NovoCure’s Gross Profit of 420.154M is higher than Glaukos Gross Profit of 227.384M.

Ebitda: NovoCure’s Ebitda of -38.384M is higher than Glaukos Ebitda of -1.474M.

P/E Ratio: NovoCure’s P/E Ratio of -130.32 is lower than Glaukos P/E Ratio of -79.43.

P/S Ratio: NovoCure’s P/S Ratio of 14.26 is lower than Glaukos P/S Ratio of 7.5.

P/B Ratio: NovoCure’s P/B Ratio of 17.6 is lower than Glaukos P/B Ratio of 3.69.

P/FCF Ratio: NovoCure’s P/FCF Ratio of 213.07 is higher than Glaukos P/FCF Ratio of -319.26.

ROE: NovoCure’s ROE of -0.14 is higher than Glaukos ROE of -0.05.

ROA: NovoCure’s ROA of -0.05 is higher than Glaukos ROA of -0.03.

Return On Capital Employed: NovoCure’s Return On Capital Employed of -0.04 is higher than Glaukos Return On Capital Employed of -0.01.

Gross Profit Margin: NovoCure’s Gross Profit Margin of 0.78 is higher than Glaukos Gross Profit Margin of 0.77.

Assets (Total): NovoCure’s Assets (Total) of 1.139B is higher than Glaukos Assets (Total) of 1.05B.

Debt (Total): NovoCure’s Debt (Total) of 575.213M is higher than Glaukos Debt (Total) of 382.375M.

Shareholders Equity: NovoCure’s Shareholders Equity of 410.494M is lower than Glaukos Shareholders Equity of 587.151M.

## NovoCure vs Hologic

Market Cap: NovoCure’s Market Cap of 7723676160 is lower than Hologic Market Cap of 17676124160.

Average Volume: NovoCure’s Average Volume of 698150.0 is higher than Hologic Average Volume of 2.074M.

Beta: NovoCure’s Beta of 0.88 is lower than Hologic Beta of 1.09.

Revenue: NovoCure’s Revenue of 535.031M is higher than Hologic Revenue of 5.632B.

Net Income: NovoCure’s Net Income of -58.351M is lower than Hologic Net Income of 1.871B.

Gross Profit: NovoCure’s Gross Profit of 420.154M is higher than Hologic Gross Profit of 3.796B.

Ebitda: NovoCure’s Ebitda of -38.384M is lower than Hologic Ebitda of 2.863B.

P/E Ratio: NovoCure’s P/E Ratio of -130.32 is lower than Hologic P/E Ratio of 11.54.

P/S Ratio: NovoCure’s P/S Ratio of 14.26 is lower than Hologic P/S Ratio of 3.31.

P/B Ratio: NovoCure’s P/B Ratio of 17.6 is lower than Hologic P/B Ratio of 3.72.

P/FCF Ratio: NovoCure’s P/FCF Ratio of 213.07 is lower than Hologic P/FCF Ratio of 6.84.

ROE: NovoCure’s ROE of -0.14 is lower than Hologic ROE of 0.36.

ROA: NovoCure’s ROA of -0.05 is lower than Hologic ROA of 0.16.

Return On Capital Employed: NovoCure’s Return On Capital Employed of -0.04 is lower than Hologic Return On Capital Employed of 0.25.

Gross Profit Margin: NovoCure’s Gross Profit Margin of 0.78 is higher than Hologic Gross Profit Margin of 0.64.

Assets (Total): NovoCure’s Assets (Total) of 1.139B is lower than Hologic Assets (Total) of 8.92B.

Debt (Total): NovoCure’s Debt (Total) of 575.213M is higher than Hologic Debt (Total) of 3.145B.

Shareholders Equity: NovoCure’s Shareholders Equity of 410.494M is higher than Hologic Shareholders Equity of 4.219B.

## About NovoCure

NovoCure Limited, an oncology company, is engaged in the development, manufacture and commercialization of tumor treatment fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan and Greater China. its TTFields devices include Optune for the treatment of glioblastoma and Optune Lua for the treatment of malignant pleural mesothelioma. the company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. NovoCure Limited was founded in 2000 and has its headquarters in Saint Helier, Jersey.